OHE https://validator.w3.org/feed/docs/rss2.html New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof) The cost of inaction on LDL cholesterol Rare Disease Day 2022 To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement No Smoking Day 2022: Reflecting on OHE Projections from 1994 Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet? The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed? NICE’s severity modifier: a step in the right direction, but still a long way to go Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB Let’s talk about (health) inequalities Accounting for Preference Heterogeneity in Discrete Choice Experiments Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients. Open Source Modelling: From Ideas to Action Sleepio: Lessons from the Frontier of Digital Therapeutics ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies? Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis The State of Play for Cost-effectiveness Thresholds Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds  Kefah Al Qawasmeh  Haider Shamsi Can HTA keep up with innovation? A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List” Evaluating novel antimicrobials within EU joint clinical assessments  OHE A Dose of Economics Mid-year health check: policy, pricing & what’s coming The disputed calculus of life Office of Health Economics latest research estimates 20 people a day die in unrelieved pain in the UK in the last 3 months of their lives Brendan Shaw The EU Joint Clinical Assessment: To boldly go where no policy has gone before? Gundo Weiler Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number OHE Deputy CEO Lotte Steuten appointed president-elect of ISPOR OHE partners with LSHTM and CMCC to bridge environmental and health economics approaches to the climate health crisis Professors Andrew Briggs and Thomas Pogge announced as the winners of the 2024 OHE Innovation Policy Prize Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report Addressing the systemic challenges of underinvestment in prevention What is your health worth? PROMs, EQ-5D & economic evaluation Hannah Hussain The impact of inflation on incremental costs in HTA Joe Trim Ella Barker Sam Large AI and the future of health economics Our team George Bray Careers at OHE When antibiotics stop working: the hidden crisis in plain sight